Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Pediatrics/Neonatology | Psychiatry/Psychology | Family Medicine
Clinical Trials: Asperger's Disorder
A listing of clinical trials currently looking for volunteers to enroll in Asperger's Disorder studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Dothan : Research Site
ConnectMe to a clinical research program in autism.
View More »
Dothan : Forest Investigative Site 068
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Arizona
Phoenix : Research Site
ConnectMe to a clinical research program in autism.
Tucson : Research Site
ConnectMe to a clinical research program in autism.
View More »
Phoenix : Forest Investigative Site 005
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Tucson : Forest Investigative Site 055
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Arkansas
Little Rock : Research Site
ConnectMe to a clinical research program in autism.
View More »
Little Rock : Forest Investigative Site 077
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
California
Imperial : Research Site
ConnectMe to a clinical research program in autism.
Los Angeles : Research Site
ConnectMe to a clinical research program in autism.
Santa Ana : Research Site
ConnectMe to a clinical research program in autism.
Stanford : Research Site
ConnectMe to a clinical research program in autism.
View More »
Glendale : Forest Investigative Site 054
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Los Angeles : Forest Investigative Site 096
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Santa Ana : Forest Investigative Site 026
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Colorado
Centennial : Research Site
ConnectMe to a clinical research program in autism.
View More »
Boulder : Forest Investigative Site 078
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Centennial : Forest Investigative Site 073
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
District of Columbia
Washington : Research Site
ConnectMe to a clinical research program in autism.
View More »
Washington : Forest Investigative Site 052
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Florida
Bradenton : Research Site
ConnectMe to a clinical research program in autism.
Jacksonville : Research Site
ConnectMe to a clinical research program in autism.
Maitland : Research Site
ConnectMe to a clinical research program in autism.
Orange City : Research Site
ConnectMe to a clinical research program in autism.
Orlando : Research Site
ConnectMe to a clinical research program in autism.
Orlando : Research Site
ConnectMe to a clinical research program in autism.
Tampa : Research Site
ConnectMe to a clinical research program in autism.
Wellington : Research Site
ConnectMe to a clinical research program in autism.
View More »
Bradenton : Forest Investigative Site 075
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Gainesville : Forest Investigative Site 080
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Jacksonville : Forest Investigative Site 117
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Maitland : Forest Investigative Site 065
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Oakland Park : Forest Investigative Site 085
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orange City : Forest Investigative Site 115
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orlando : Forest Investigative Site 062
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orlando : Forest Investigative Site 114
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Orlando : Forest Investigative Site 125
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Tampa : Forest Investigative Site 067
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Wellington : Forest Investigative Site 101
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Illinois
Libertyville : Forest Investigative Site 102
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Naperville : Forest Investigative Site 023
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Indiana
Indianapolis : Research Site
ConnectMe to a clinical research program in autism.
Indianapolis : Research Site
ConnectMe to a clinical research program in autism.
View More »
Evansville : Forest Investigative Site 082
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Fort Wayne : Forest Investigative Site 123
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Indianapolis : Forest Investigative Site 056
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Indianapolis : Forest Investigative Site 084
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Kansas
Wichita : Research Site
ConnectMe to a clinical research program in autism.
View More »
Wichita : Forest Investigative Site 106
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Kentucky
Louisville : Research Site
ConnectMe to a clinical research program in autism.[DISABLED]
View More »
Louisville : Forest Investigative Site 061
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Owensboro : Forest Investigative Site 074
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Louisiana
Lake Charles : Research Site
ConnectMe to a clinical research program in autism.
Lake Charles : Lake Charles Clinical Trials
Safety and Tolerability Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Lake Charles : Lake Charles Clinical Trials
Safety and Tolerability Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
View More »
Lake Charles : Forest Investigative Site 095
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Maryland
Rockville : Research Site
ConnectMe to a clinical research program in autism.
View More »
Rockville : Forest Investigative Site 086
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Massachusetts
Newton : Forest Investigative Site 059
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Nebraska
Lincoln : Research Site
ConnectMe to a clinical research program in autism.
View More »
Lincoln : Forest Investigative Site 097
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Lincoln : Forest Investigative Site 116
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Nevada
Las Vegas : Research Site
ConnectMe to a clinical research program in autism.
Las Vegas : Research Site
ConnectMe to a clinical research program in autism.
View More »
Henderson : Forest Investigative Site 130
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Las Vegas : Forest Investigative Site 104
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
New Jersey
Toms River : Forest Investigative Site 127
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
New Mexico
Albuquerque : Research Site
ConnectMe to a clinical research program in autism.
Albuquerque : Research Site
ConnectMe to a clinical research program in autism.
View More »
Albuquerque : Forest Investigative Site 081
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Albuquerque : Forest Investigative Site 107
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
North Carolina
Chapel Hill : Research Site
ConnectMe to a clinical research program in autism.
View More »
Chapel Hill : Forest Investigative Site 072
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Ohio
Columbus : Research Site
ConnectMe to a clinical research program in autism.
View More »
Avon Lake : Forest Investigative Site 069
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Columbus : Forest Investigative Site 001
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Oklahoma
Oklahoma City : Research Site
ConnectMe to a clinical research program in autism.
Tulsa : Research Site
ConnectMe to a clinical research program in autism.
View More »
Oklahoma City : Forest Investigative Site 019
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Tulsa : Forest Investigative Site 092
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Oregon
Gresham : Research Site
ConnectMe to a clinical research program in autism.
View More »
Gresham : Forest Investigative Site 053
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Pennsylvania
McMurray : Research Site
ConnectMe to a clinical research program in autism.
Media : Research Site
ConnectMe to a clinical research program in autism.
View More »
Johnstown : Forest Investigative Site 132
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
McMurray : Forest Investigative Site 131
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Media : Forest Investigative Site 100
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
South Carolina
Charleston : Research Site
ConnectMe to a clinical research program in autism.
Tennessee
Memphis : Research Site
ConnectMe to a clinical research program in autism.
Nashville : Research Site
ConnectMe to a clinical research program in autism.
View More »
Memphis : Forest Investigative Site 090
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Nashville : Forest Investigative Site 057
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Texas
Houston : Research Site
ConnectMe to a clinical research program in autism.
The Woodlands : Research Site
ConnectMe to a clinical research program in autism.
View More »
Houston : Forest Investigative Site 051
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
The Woodlands : Forest Investigative Site 070
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Utah
Salt Lake City : Research Site
ConnectMe to a clinical research program in autism.
Salt Lake City : CRI Lifetree
The objective of this study is to evaluate the safety and tolerability of memantine in
pediatric (6-12 years old) patients with autism, Asperger’s Disorder, or Pervasive
Developmental Disorder Not Otherwise Specified (PDD-NOS) and to identify responders for participation in the follow-up randomized withdrawal study.
View More »
Clinton : Forest Investigative Site 028
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Salt Lake City : Forest Investigative Site 029
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Virginia
Norfolk : Research Site
ConnectMe to a clinical research program in autism.
View More »
Norfolk : Forest Investigative Site 113
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Washington
Bothell : Research Site
ConnectMe to a clinical research program in autism.
View More »
Bothell : Forest Investigative Site 071
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
West Virginia
Charleston : Research Site
ConnectMe to a clinical research program in autism.
View More »
Charleston : Forest Investigative Site 119
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Wisconsin
Middleton : Forest Investigative Site 063
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
